logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation

Hangzhou AGS Medtech(688581.SH) granted 391,500 restricted shares at a price of 70 yuan per share.

date
18:42 07/09/2023
avatar
GMT Eight
Hangzhou AGS Medtech(688581.SH) announcement, the restrictive stock grant conditions stipulated in the company's 2023 restricted stock incentive plan have been achieved. The company has determined September 7, 2023 as the initial grant date for the restricted stocks of this equity incentive plan. It will grant 391,500 restricted stocks at a price of 70 yuan per share to 69 eligible incentive recipients.
Related Articles
PROSP INV HOLD (00310) has subscribed 612,000 Hong Kong dollars for the shares of the listed company. Trading will resume on March 13th.
HK Stock
VISEN PHARMA-B(02561) released its annual performance, with research and development costs reaching 93.48 million yuan, an increase of 3.27% year-on-year.
US Stock Market Move | Himax Technologies, Inc. Sponsored ADR (HIMX.US) soared over 23% in early trading, accumulating a 52% increase over the past 4 trading days.
PROSP INV HOLD (00310) has subscribed 612,000 Hong Kong dollars for the shares of the listed company. Trading will resume on March 13th.
VISEN PHARMA-B(02561) released its annual performance, with research and development costs reaching 93.48 million yuan, an increase of 3.27% year-on-year.
HK Stock
US Stock Market Move | Himax Technologies, Inc. Sponsored ADR (HIMX.US) soared over 23% in early trading, accumulating a 52% increase over the past 4 trading days.
RECOMMEND
“A+H” Team Continues To Expand Hard Technology Firms Accelerate Global Deployment
“A+H” Team Continues To Expand Hard Technology Firms Accelerate Global Deployment
icon
11/03/2026
Anti‑Stagflation Theme Guides Hong Kong Allocation Institutions Identify Power And Energy Assets As Short‑Term Core
Anti‑Stagflation Theme Guides Hong Kong Allocation Institutions Identify Power And Energy Assets As Short‑Term Core
icon
11/03/2026
U.S. Equities Enter “Always‑On” Trading Era Nasdaq Advances Stock Tokenization Framework
U.S. Equities Enter “Always‑On” Trading Era Nasdaq Advances Stock Tokenization Framework
icon
11/03/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.